Diabetes

New-Onset Type 2 Diabetes Linked to Higher Cancer Risk

May 8th 2025

A validated questionnaire assesses skills, knowledge, and attitudes for effective gestational diabetes management.

Diabetes monitoring | Image credit: abidika - stock.adobe.com

FQHCs Show Low Engagement in Hypertension, Diabetes Trials

April 23rd 2025

Rural health sign | Image credit: BJP7images - stock.adobe.com

Housing Instability Linked to Worse Type 2 Diabetes Outcomes

April 15th 2025

AI representation of housing stability | Image credit: GoldPumaze - stock.adobe.com

GLP-1 RAs, SGLT2 Inhibitors Associated With Reduced MACE, HHF in Patients With Diabetes

April 14th 2025

Diabetes concept | Image credit: Sherry Young - stock.adobe.com

Study: Racial-Ethnic Disparities in T1D Technology Use Worsened From 2017 to 2019

April 9th 2025

More News

December 15th 2021

Between coverage years 2017 and 2019, racial-ethnic disparities in diabetes technology use worsened among Medicare beneficiaries with type 1 diabetes.

December 8th 2021

Experts Examine the Association Between Retinal Damage, DKD Presence in Patients With T2D

Results of a cross-sectional study fond diabetic kidney disease (DKD) was associated with retinal changes in patients with type 2 diabetes (T2D).

December 6th 2021

Review: Smartphone Apps May Improve Outcomes in Gestational Diabetes

Results of a systemic review found evidence potentially supporting the use of smart phone applications among mothers with gestational diabetes.

December 1st 2021

Does Gender-Affirming Hormone Therapy Affect T2D Risk?

Results of a cohort study showed that transfeminine individuals may be at a higher risk for type 2 diabetes (T2D) compared with cisgender females, but revealed little evidence that gender-affirming hormone therapy impacts diabetes risk.

November 29th 2021

Variability in Statin Use Seen Among Finnish T2D Population

Data showed differences in statin use to prevent cardiovascular disease among Finnish patients with type 2 diabetes.

November 22nd 2021

Contributor: CMS Has Decided to Put Its Muscle Behind Glycemic Management—Why Now?

Jordan Messler, MD, SFHM, FACP

CMS' introduction of 3 new electronic clinical quality measures, 2 of which are focused on inpatient glycemic management, signal a strong commitment to shine a light on this often-overlooked area, according to the chief medical officer at Glytec.

November 16th 2021

Dr Robert Gabbay Outlines How the Health Equity Now Initiative Addresses Diabetes Care Disparities

Robert A. Gabbay, MD, PhD, chief scientific and medical officer at the American Diabetes Association, explains the Health Equity Now initiative and how it shines a light on health disparities.

November 10th 2021

Dr Robert Gabbay on COVID-19 Vaccinations in the Diabetes Community

Robert A. Gabbay, MD, PhD, chief scientific and medical officer at the American Diabetes Association, discusses COVID-19 vaccinations among people with diabetes as they have been disproportionally affected by the pandemic.

November 10th 2021

Challenges With Implementing the Diabetes Prevention Program for Medicare Beneficiaries in an Integrated Health System

Inga Gruß, PhD Alison Firemark, MA Dea Papajorgji-Taylor, MPH Stephanie L. Fitzpatrick, PhD

This study presents challenges of implementing the CDC-approved Diabetes Prevention Program for Medicare beneficiaries at a large, integrated health care delivery system.

November 8th 2021

Analysis Details Factors Associated With T2D Development Among Women With PCOS

Results of a cross-sectional study detail characteristics among women with polycystic ovary syndrome (PCOS) who develop type 2 diabetes.

November 3rd 2021

Study Evaluates Impact of Food Environments on T2D Risk

Results of a longitudinal study indicate community food accessibility factors may impact type 2 diabetes risk among veterans.

October 31st 2021

Research Highlights Racial/Ethnic Diabetes Disparities Based on Age of Diagnosis

New research underscores racial/ethnic diabetes disparities in the United States.

October 29th 2021

Dr Robert Gabbay Discusses SGLT2 Inhibitor Uptake Among Cardiologists, Nephrologists

As time goes on, we're finding out more and more benefits of sodium glucose co-transporter 2 (SGLT2) inhibitors, said Robert A. Gabbay, MD, PhD, the chief science and medical officer at the American Diabetes Association.

October 26th 2021

Intensifying Diabetes Medication Regimen at Hospital Discharge May Not Benefit Older Patients

Results of a retrospective study found no benefits among older patients whose diabetes medication was intensified following short hospital admissions.

October 20th 2021

Hypoglycemia Upon Hospital Admission From Long-term Care: Health Care Resource Use

Naushira Pandya, MD, CMD Alyssa Trenery, PharmD, MPH Ray Sieradzan, PharmD Claudia Gabai, MPH Anastasia Ermakova, PharmD Yan Xiong, MS

This analysis of a hospital billing database describes inpatient length of stay, intensive care unit length of stay, comorbidities, and costs for patients with diabetes after admission with hypoglycemia from long-term care or home.

October 18th 2021

Insulin Analogs, Pen Delivery Devices Most Used Among Patients With T2D

Using data from a nationally representative sample, investigators sought to determine trends in insulin device use.

October 15th 2021

Light Drinking Linked With Lower Risk of Type 2 Diabetes for Some Women

Some alcohol, but not more than 1 drink per day, was linked to a 55% lower risk of type 2 diabetes in women with a history of gestational diabetes.

October 11th 2021

Study Finds Statin Use Associated With Diabetes Progression

Using electronic medical record data from Veterans Affairs, researchers found statin use was associated with a greater risk of diabetes progression.

October 8th 2021

Patient and Supporter Factors Affecting Engagement With Diabetes Telehealth

Margaret F. Zupa, MD John D. Piette, PhD Shelley C. Stoll, MPH D. Scott Obrosky, MS Monique Boudreaux-Kelly, PhD Ada O. Youk, PhD Luc Overholt, MD Ranak Trivedi, PhD Michele Heisler, MD, MPH Ann-Marie Rosland, MD, MS

Family support with medication management and recent urgent self-management concerns are 2 novel factors, among others, that predict completion of diabetes telehealth calls.

October 4th 2021

Diabetic Nephropathy, Obesity Increase COVID-19 Mortality Risk in Patients With Type 2 Diabetes

Patients with T2D had elevated blood glucose levels but there were no notable differences in levels between surviving and non-surviving patients with T2D.

September 29th 2021

Dr Deepak Bhatt on the Importance of In-Hospital Initiation of SGLT2 Inhibitors

Deepak L. Bhatt, MD, MPH, outlines the benefits of starting patients on sodium glucose co-transporter 2 (SGLT2) inhibitors while they are hospitalized.

September 27th 2021

Medicaid Expansion Linked With Reduction in Uninsurance and Improved Blood Pressure, Glucose Control Measures

Results of a representative study of patients at federally qualified health centers found Medicaid expansion was associated with reduced rates of uninsurance, improved blood pressure and diabetes control measures, and progress in closing racial care disparities over 5 years.

September 21st 2021

Managing the Surge: Delayed Chronic Wound Care During COVID-19

David G. Armstrong, DPM, MD, PhD

September 20th 2021

Encourage Further SGLT2 Inhibitor Treatment for Diabetes, Kidney Disease, Expert Says

New data from the CREDENCE trial shows that the sodium glucose co-transporter 2 (SGLT2) inhibitor canagliflozin may reduce hyperkalemia risk in people with type 2 diabetes and chronic kidney disease who are using RAAS inhibitors.

September 10th 2021

Presentation Outlines Long-term CV Risks of Gestational Diabetes

A session at the 5th annual Heart in Diabetes Conference highlights the long-term risks of gestational diabetes.

September 10th 2021

Research Highlights Benefits of Aspirin, Monoclonal Antibody Use in Patients With Diabetes, COVID-19

New research presented at the 5th Heart in Diabetes Conference highlights potential therapeutic options for patients with COVID-19 and diabetes.

September 9th 2021

FDA Grants Empagliflozin Breakthrough Therapy Designation in HFpEF

Mary Caffrey

The sodium glucose co-transporter 2 (SGLT2) inhibitor reduced cardiovascular death and hospitalization for heart failure by 21% in results presented August 27 during the recent European Society of Cardiology Congress.

September 7th 2021

Dr David McIntyre on Care Takeaways From COVID-19 for Pregnant Patients With Diabetes

David McIntyre, MD, FRACP, describes lessons learned from the pandemic for ensuring appropriate continuation of care for pregnant patients with diabetes.

September 2nd 2021

Increase in Both Type 1 and Type 2 Diabetes Seen Among US Youth Over 16-Year Period